Category: biotech/medical – Page 1994
A lab worker in San Diego became infected with a smallpox-related virus, known as the vaccinia virus, after she accidentally stuck her finger with a needle, according to a new report.
The infection caused the tip of the woman’s finger to swell and turn black. Her case is unique because it marks the first time that doctors have used tecovirimat — a recently approved drug for smallpox — to treat a laboratory-acquired infection with vaccinia virus, the report said.
Emma doesn’t look so great.
Her legs are puffy and covered in varicose veins. Her eyes are flat and dead, and her back looks like she spends her days ringing the bell at Notre-Dame Cathedral.
It’s harsh but true. Emma is a life-sized doll depicting what the average office worker in the United Kingdom could look like in 20 years if changes aren’t made to the workplace environment.
Scientists have developed a new gene-editing technology that could potentially correct up to 89% of genetic defects, including those that cause diseases like sickle cell anemia.
The new technique is called “prime editing,” and was developed by researchers from the Broad Institute of MIT and Harvard, who published their findings Monday in the journal Nature.
Prime editing builds on powerful CRISPR gene editing, but is more precise and versatile — it “directly writes new genetic information into a specified DNA site,” according to the paper.
Nearly half the U.S. population is projected to have one or more chronic conditions by 2030 and the need to better manage both care delivery and costs has never been greater.
At the same time, Baby Boomers are entering their “Golden Years” and seeking out preventative and lifestyle medicine to ensure that they live longer and with more personal freedom. And they want to do all of this while “aging in place” and not being relegated to the decrepit and outdated nursing homes of their own parents’ generation. After all, we live in a new era of instant song selection, streaming movies, and Amazon home delivery.
A technology designed to preserve synapses across the whole brain of a large mammal is successful
Using a combination of ultrafast glutaraldehyde fixation and very low temperature storage, researchers have demonstrated for the first-time ever a way to preserve a brain’s connectome (the 150 trillion synaptic connections presumed to encode all of a person’s knowledge) for centuries-long storage in a large mammal. This laboratory demonstration clears the way to develop Aldehyde-Stabilized Cryopreservation into a ‘last resort’ medical option, one that would prevent the destruction of the patient’s unique connectome, offering at least some hope for future revival via mind uploading. You can view images and videos demonstrating the quality of the preservation method for yourself at the evaluation page.
New cellular and molecular processes underlying communication between gut microbes and brain cells have been described for the first time by scientists at Weill Cornell Medicine and Cornell’s Ithaca campus.
Over the last two decades, scientists have observed a clear link between autoimmune disorders and a variety of psychiatric conditions. For example, people with autoimmune disorders such as inflammatory bowel disease (IBD), psoriasis and multiple sclerosis may also have depleted gut microbiota and experience anxiety, depression and mood disorders. Genetic risks for autoimmune disorders and psychiatric disorders also appear to be closely related. But precisely how gut health affects brain health has been unknown.
“Our study provides new insight into the mechanisms of how the gut and brain communicate at the molecular level,” said co-senior author Dr. David Artis, director of the Jill Roberts Institute for Research in Inflammatory Bowel Disease, director of the Friedman Center for Nutrition and Inflammation and the Michael Kors Professor of Immunology at Weill Cornell Medicine. “No one yet has understood how IBD and other chronic gastrointestinal conditions influence behavior and mental health. Our study is the beginning of a new way to understand the whole picture.”
Watch Video
In this lesson, Chris Wark shares a sneak peek into the diet, mind-set, and daily practices that helped him beat stage three-C colon cancer at the age of 26. Through the details of his amazing healing journey, you’ll discover the alternatives to traditional chemotherapy that helped him heal cancer painlessly and while maintaining his vigor and zest for life.
You’ll learn…
Two major U.S. biomedical research funders plan to each put at least $100 million over 4 years toward bringing cutting-edge, gene-based treatments to a part of the world that often struggles to provide access to even basic medicines: sub-Saharan Africa. The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation today announced the unusual collaboration to launch clinical trials for gene-based cures for HIV and sickle cell disease within the region in the coming decade.
The ambitious goal is to steer clear of expensive, logistically impractical strategies that require stem cell transplantation, and instead develop simpler, affordable ways of delivering genes or gene-editing drugs that can cure these diseases. “Yes, this is audacious,” NIH Director Francis Collins said during a press teleconference this morning on the project. “But if we don’t put our best minds, resources, and visions together right now, we would not live up to our mandate to bring the best science to those who are suffering.”
After decades of work and setbacks, the traditional gene therapy approach of delivering DNA into the body to replace a defective gene or boost a protein’s production is now reaching the clinic for several diseases, including inherited blindness, neuromuscular disease, and leukemia. Animal studies and some clinical trials have suggested that two diseases prevalent in Africa, HIV and sickle cell disease, can be treated by gene therapies or newer genome-editing tools such as CRISPR.